Brief: ARCA Biopharma Announces Second Quarter 2023 Financial Results
21/07/2023 21:29
July 21 (Reuters) - ARCA Biopharma Inc ABIO.O :
* ARCA BIOPHARMA ANNOUNCES SECOND QUARTER 2023 FINANCIAL
RESULTS
* ARCA BIOPHARMA INC - CASH AND CASH EQUIVALENTS WERE $40.2
MILLION AS OF JUNE 30, 2023
* ARCA BIOPHARMA INC - QTRLY NET LOSS PER SHARE $0.10
* ARCA BIOPHARMA - ENGAGED IN STRATEGIC REVIEW PROCESS,
EVALUATING
ADDITIONAL DEVELOPMENT OF ITS ASSETS, COLLABORATIONS, OTHER
STRATEGIC OPTIONS
* ARCA BIOPHARMA INC - COMPANY AND LADENBURG HAVE REVIEWED
SEVERAL POTENTIAL STRATEGIC TRANSACTIONS
Source text for Eikon: ID:nGNX97c9bZ
Further company coverage: ABIO.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Oruka Therapeutics
See all newsOruka falls after reporting mid-stage data for psoriasis drug
Brief: Oruka Therapeutics Announces Positive Week 28 Data For Orka-001 From The Ongoing Everlast-A Trial Showing Deepening Of Responses Without Additional Dosing
Brief: Oruka Therapeutics Appoints Todd Edwards As Chief Commercial Officer
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Oruka Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary